Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood flow and oxygen supply to the muscles during exercise. In fac...
Main Authors: | Shalini Murali Krishnan, Johannes Nordlohne, Lisa Dietz, Alexandros Vakalopoulos, Petra Haning, Elke Hartmann, Roland Seifert, Jörg Hüser, Ilka Mathar, Peter Sandner |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/15/8016 |
Similar Items
-
Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy
by: Brigida Boccanegra, et al.
Published: (2023-04-01) -
A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys
by: Michael St. Andre, et al.
Published: (2017-11-01) -
The Effect of Deflazacort Treatment on the Functioning of Skeletal Muscle Mitochondria in Duchenne Muscular Dystrophy
by: Mikhail V. Dubinin, et al.
Published: (2020-11-01) -
G-CSF does not influence C2C12 myogenesis despite receptor expression in healthy and dystrophic skeletal muscle
by: Craig Robert Wright, et al.
Published: (2014-05-01) -
TRPCs: Influential Mediators in Skeletal Muscle
by: Jun Hee Choi, et al.
Published: (2020-04-01)